Researchers plot huge HIV study; Novavax posts positive Ebola data;

@FierceBiotech: ICYMI yesterday: Tekmira changes its name and shuffles away from Ebola. News | Follow @FierceBiotech

@JohnCFierce: ICYMI: Adaptimmune touts a promising snapshot of TCRs for myeloma. More | Follow @JohnCFierce

@DamianFierce: You can watch The Atlantic's AAIC2015-adjacent chat thing, ft. $LLY, here. | Follow @DamianFierce

> Researchers are planning the largest-ever trial for an HIV treatment, seeking to replicate results from a small group of people who, after receiving post-infection treatment, managed to remain virus-free without further dosing. More

> Novavax's in-development Ebola vaccine generated positive top-line data in a Phase I study, demonstrating immunogenicity and tolerability. News

> Clinical trial technology outfit Medidata ($MDSO) is looking to expand its footprint in Asia, betting on continued growth in demand for biopharma R&D in the region. Story

Medical Device News

@FierceMedDev: Alere revs up engine with new deals and win for quick strep test. FierceDiagnostics story | Follow @FierceMedDev

@VarunSaxena2: ICYMI: Indian stentmakers gaining global foothold--is U.S. market next? More | Follow @VarunSaxena2

@EmilyWFierce: Kim Kardashian speaks out for Duchesnay's morning sickness drug, Diclegis. FiercePharmaMarketing press release | Follow @EmilyWFierce

> Boston Scientific faces reimbursement hurdles for lung-searing asthma treatment. Story

> UCLA adopts startup cleaning system to help stop spread of superbugs via duodenoscopes. Article

Pharma News

@FiercePharma: India's Torrent completes deal to buy family-run Zyg Pharma, gets FDA plant. More from FiercePharmaAsia | Follow @FiercePharma

@CarlyHFierce: ICYMI: Bayer homes in on €10B plastics IPO with plans for summer roadshow. Report | Follow @CarlyHFierce

> Novartis looks past dim Q2 results to new Glatopa, Entresto launches. Article

> Actelion's Opsumit growth heralds smooth switch off aging Tracleer. Report

Drug Delivery News

> Two oral therapeutics specialists bag a combined $140M via IPO, VC funding. Item

> Glucose delivery pathway that feeds tumors could be exploited to knock them down. More

> Minimally invasive brain probe uses light flashes to target drugs. Story

> Purdue team developing smart capsule for diseases of the large intestine. Report

> Novo to sell shield for concealing the needle of its injection pens. Article

Pharma Manufacturing News

> Biogen gets all of North Carolina site from Eisai as part of manufacturing build-out. Story

> Amgen's Colorado plant hits the market for $85M. Item

> Valeant gets manufacturing in Middle East with deal for Amoun. More

> Baxter IDs particulate in recalled saline as insects. Article

> AMRI picks up Spanish drugmaker in $174M deal. News

Pharma Asia News

> AdvaMed welcomes legislation to separate India's device and drug oversight. Item

> ASLAN and Singapore's NCCS plan studies on Asia-prevalent cancers. More

> India's Sun Pharma sees multiyear earnings hit as it fixes plants, integrates Ranbaxy. Report

> Medidata's de Vries on disruption in Asia drug research with Japan a focus. Story

> Singapore's biopharma industry: Where the jobs are. Article

Suggested Articles

Dewpoint Therapeutics aims to advance research in one of the more mysterious cell organelles: biomolecular condensates.

The FDA slapped a partial clinical hold on the phase 2/3 study of Inovio’s COVID-19 vaccine because it has “additional questions” about the trial.

Preclinical inflammatory disease biotech Ilias Biologics has grabbed a $20.6 million funding round as it eyes a 2021 human test of its leading asset.